argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
623.82
-2.21 (-0.35%)
Dec 20, 2024, 4:00 PM EST - Market closed
argenx SE Revenue
argenx SE had revenue of $588.88M in the quarter ending September 30, 2024, with 73.28% growth. This brings the company's revenue in the last twelve months to $1.91B, up 85.56% year-over-year. In the year 2023, argenx SE had annual revenue of $1.27B with 187.66% growth.
Revenue (ttm)
$1.91B
Revenue Growth
+85.56%
P/S Ratio
n/a
Revenue / Employee
$1,662,595
Employees
1,148
Market Cap
38.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.27B | 827.59M | 187.66% |
Dec 31, 2022 | 441.01M | -87.26M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | 92.81M | 63.58M | 217.51% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Takeda Pharmaceutical | 31.73B |
GE HealthCare Technologies | 19.56B |
IQVIA Holdings | 15.32B |
Haleon | 15.07B |
Alcon | 9.76B |
Agilent Technologies | 6.51B |
Edwards Lifesciences | 6.31B |
ResMed | 4.81B |
ARGX News
- 26 days ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - GlobeNewsWire
- 4 weeks ago - Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics - Business Wire
- 5 weeks ago - argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China - GlobeNewsWire
- 5 weeks ago - Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Business Wire
- 6 weeks ago - argenx to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat - Seeking Alpha
- 7 weeks ago - argenx SE (ARGX) Q3 2024 Earnings Call Transcript - Seeking Alpha